Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,500.00
(
0.43%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
107.12
(
0.05%
)
Bitcoin
69,005.55
(
0.21%
)
News Focus
News Focus
Post# of 257364
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122852
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dav1234 post# 154824

Thursday, 01/03/2013 10:08:13 AM

Thursday, January 03, 2013 10:08:13 AM

Post# of 257364
ABT’s Xience Xpedition is an incremental improvement; it’s not a big deal from a business standpoint insofar as the Xience family was already the market leader.

Of more consequence to ABT’s top and bottom lines will be the launch of the bioresorbable drug-eluting stent in the US, pending the reporting of data from the US pivotal study.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today